Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
University of Nebraska
National Institutes of Health Clinical Center (CC)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Seagen Inc.
Massachusetts General Hospital
Samsung Medical Center